Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
The nonalcoholic steatohepatitis (NASH) market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.
The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Selonsertib & Cenicriviroc
By Sales Channel
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Allergan plc. (Tobira Therapeutics)
Cadila Healthcare Limited
Conatus Pharmaceuticals Inc.
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Novartis International AG
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets, 2021
3.2.2. Top player positioning
3.3. Top winning strategies
3.4. MARKET DYNAMICS
22.214.171.124. Upsurge in NASH-affected population
126.96.36.199. Rise in prevalence of diabetes & obesity
188.8.131.52. Surge in healthcare expenditures worldwide
184.108.40.206. Insufficient diagnostic technologies for NASH
220.127.116.11. Poor demand in the underdeveloped countries
18.104.22.168. Strong presence of pipeline drugs
22.214.171.124. Unmet needs for NASH therapeutics
126.96.36.199. Growth opportunities in the emerging markets
3.4.4. Impact analyses
3.5. Pipeline analyses
CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE
4.1.1. Market size and forecast
4.2. Vitamin E & pioglitazone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.3. Obeticholic acid
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Selonsertib & cenicriviroc
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.3. Online providers
5.3.1. Market size and forecast, by region
5.4. Retail pharmacy
5.4.1. Market size and forecast, by region
CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
188.8.131.52. U.S. market size and forecast
184.108.40.206. Canada market size and forecast
220.127.116.11. Mexico market size and forecast
6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
18.104.22.168. Germany market size and forecast
22.214.171.124. France market size and forecast
126.96.36.199. UK market size and forecast
188.8.131.52. Italy market size and forecast
184.108.40.206. Spain market size and forecast
220.127.116.11. Rest of Europe market size and forecast
6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
18.104.22.168. Japan market size and forecast
22.214.171.124. China market size and forecast
126.96.36.199. Australia market size and forecast
188.8.131.52. India market size and forecast
184.108.40.206. South Korea market size and forecast
220.127.116.11. Rest of Asia-Pacific market size and forecast
6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
18.104.22.168. Brazil market size and forecast
22.214.171.124. Saudi Arabia market size and forecast
126.96.36.199. South Africa market size and forecast
188.8.131.52. Rest of LAMEA market size and forecast
6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc (Tobira Therapeutics Inc.)
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Cadila Healthcare Ltd.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.3. Conatus Pharmaceuticals, Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Galmed Pharmaceuticals Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Gemphire Therapeutics Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments
7.6. Genfit SA
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Gilead Sciences, Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Intercept Pharmaceuticals, Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis International AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Shire plc
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Non-alcoholic steatohepatitis (SH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are aware of their condition. SH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of SH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of SH due to the lack of ideal diagnostic technologies limit the growth of the SH market.
At present, there is no FDA-approved drug available in the market for the treatment of SH. Lifestyle interventions are the first-line approach to mage patients with SH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in SH patients.
Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.
Key Findings of the Non-alcoholic Steatohepatitis (SH) Market:
Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025.
Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.
North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of SH along with the increase in prevalence of diabetes & obesity and rise in awareness of SH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the SH market in Asia-Pacific region.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.